IP Library › Granted Patent US 12,692,261
Granted Patent B2
US 12,692,261 · App. 18/018,216 · Granted Jul 28, 2026

Substituted heterocyclic compounds and therapeutic uses thereof

Inventors: Volker Schulze (Hohen Neuendorf, DE); Anne Mengel (Berlin, DE); Clara Adelaide Faria Alvares De Lemos (Berlin, DE); Sven Christian (East Boston, MA); Ulf Bömer (Glienicke, DE); Roman Hillig (Berlin, DE); Christian Lechner (Berlin, DE); Jérémie Xavier Mortier (Berlin, DE); Stefan Kaulfuss (Berlin, DE); Steven Corsello (Boston, MA); Katarzyna Handing (Framingham, MA); Amael Madec (Boston, MA); Laura Furst (Somerville, MA); Mrinal Shekhar (Quincy, MA); Markus Berger (Berlin, DE); Rajesha Rupaimoole (North Billerica, MA); Philip Lienau (Berlin, DE); Douglas Orsi (Watertown, MA); David McKinney (Cambridge, MA); Krzysztof Brzezinka (Berlin, DE)
Assignees: Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
C07D471/04A61P35/00C07D401/06C07D401/14C07D405/14C07D487/04C07F7/0812
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,261
App. No.
18/018,216
Granted
Jul 28, 2026
Kind
B2
Abstract

Compounds of formula (I), process for their production and their use as pharmaceuticals.

Claims (230)

1 . A compound of formula (I)

wherein:

A represents a group selected from:

X represents N, C—H, C—F, C—Cl, or C-Me;

Y represents N, or C—R 4a ;

Z represents N, or C—R 4b ,

wherein none or one of X, Y, and Z represent N;

R 1b represents hydrogen or halogen;

R 1c represents hydrogen or fluoro;

R 1e represents hydrogen or fluoro;

R 1f represents hydrogen or fluoro;

R 1g represents hydrogen or fluoro;

R 2 represents C 1 -C 3 -haloalkyl, or C 1 -C 3 -hydroxyalkyl;

R 3 represents phenyl, wherein said phenyl is independently optionally substituted, one or more times, with halogen, methyl, methoxy, C 1 -C 2 -haloalkyl, or C 1 -C 2 -haloalkoxy;

R 4a represents hydrogen, halogen, C 1 -C 3 -alkyl, C 2 -alkenyl, methoxy, difluoromethoxy, C 3 -cycloalkyl, 4-membered heterocycloalkyl, cyclopropyloxy, 4-membered heterocycloalkyl-O— or R 5a R 6a N—;

R 4b represents hydrogen, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 1 -C 3 -haloalkyl-CH 2 —, C 1 -C 3 -alkoxy, C 1 -C 3 -haloalkoxy, C 3 -C 5 -cycloalkyl, C 3 -C 5 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -C 5 -cycloalkyl-O—, C 3 -C 5 -cycloalkyl-CH 2 —O—, piperazin-1-yl, morpholin-4-yl, 3- to 6-membered heterocycloalkyl connected via a carbon atom thereof, pyrrolidin-2-one, piperidin-2-one, morpholin-3-one, 4-methylpiperazin-2-one, 3- to 6-membered heterocycloalkyl-O—, 3- to 6-membered heterocycloalkyl-CH 2 —O—, C 1 -C 3 -alkoxy-C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-C 2 -C 3 -alkoxy-, C 1 -C 4 -hydroxyalkyl, or C 1 -C 4 -hydroxyalkyl-O—;

wherein said C 3 -C 5 -cycloalkyl, C 3 -C 5 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -C 5 -cycloalkyl-O—, C 3 -C 5 -cycloalkyl-CH 2 —O—, 3- to 6-membered heterocycloalkyl, pyrrolidin-2-one, piperidin-2-one, morpholin-3-one, 4-methylpiperazin-2-one, 3- to 6-membered heterocycloalkyl-O—, 3- to 6-membered heterocycloalkyl-CH 2 —O—, piperazin-1-yl, morpholin-4-yl, C 1 -C 3 -alkoxy-C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-C 2 -C 3 -alkoxy-, C 1 -C 4 -hydroxyalkyl, and C 1 -C 4 -hydroxyalkyl-O-groups are optionally substituted, one, two or three times, with halogen, methyl, or methoxy;

R 5a represents hydrogen or methyl;

R 6a represents hydrogen or methyl, or

R 5a and R 6a , together with the nitrogen atom to which they are attached, represent a 4-membered heterocyclic ring, wherein said heterocyclic ring is optionally substituted with methyl;

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

2 . The compound of formula (I) according to claim 1 , wherein:

A represents a group selected from:

X represents N, C—H, C—F or C—Cl;

Y represents N or C—R 4a ;

Z represents N, or C—R 4b ,

wherein none or one of X, Y, and Z represent N;

R 1b represents hydrogen or fluoro;

R 1c represents hydrogen;

R 1e represents hydrogen;

R 1f represents hydrogen or fluoro;

R 1g represents hydrogen or fluoro;

R 2 represents C 1 -C 3 -haloalkyl, or C 1 -C 3 -hydroxyalkyl;

R 3 represents phenyl, wherein said phenyl is independently optionally substituted, one or more times, with halogen, methyl or C 1 -haloalkyl;

R 4a represents hydrogen, halogen, C 1 -alkyl, C 2 -alkenyl, C 3 -cycloalkyl, 4-membered heterocycloalkyl, or R 5a R 6a N—;

R 4b represents hydrogen, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 1 -C 3 -haloalkyl-CH 2 —, C 1 -C 3 -alkoxy, C 1 -C 3 -haloalkoxy, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -C 4 -cycloalkyl-O—, C 3 -C 4 -cycloalkyl-CH 2 —O—, piperazin-1-yl, morpholin-4-yl, 3- to 6-membered heterocycloalkyl connected via a carbon atom thereof, pyrrolidin-2-one, piperidin-2-one, morpholin-3-one, 4-methylpiperazin-2-one, 3- to 6-membered heterocycloalkyl-O—, 3- to 6-membered heterocycloalkyl-CH 2 —O—, C 1 -C 3 -alkoxy-C 2 -C 3 -alkoxy-, C 1 -C 4 -hydroxyalkyl, or C 1 -C 4 -hydroxyalkyl-O—,

wherein said C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -C 4 -cycloalkyl-O—, C 3 -C 4 -cycloalkyl-CH 2 —O—, 3- to 6-membered heterocycloalkyl, pyrrolidin-2-one, piperidin-2-one, morpholin-3-one, 4-methylpiperazin-2-one, 3- to 6-membered heterocycloalkyl-O—, 3- to 6-membered heterocycloalkyl-CH 2 —O—, piperazin-1-yl, morpholin-4-yl, C 1 -C 3 -alkoxy-C 2 -C 3 -alkoxy-, C 1 -C 4 -hydroxyalkyl and C 1 -C 4 -hydroxyalkyl-O-groups are optionally substituted, one or two times, with halogen or methyl;

R 5a represents hydrogen or methyl;

R 6a represents hydrogen or methyl, or

R 5a and R 6a , together with the nitrogen atom to which they are attached, represent a 4-membered heterocyclic ring;

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

3 . The compound of formula (I) according to claim 2 , wherein:

A represents:

X represents C—H, C—F;

Y represents N or C—R 4a ;

Z represents N or C—R 4b ;

wherein none or one of Y and Z represent N;

R 1b represents hydrogen or fluoro;

R 1e represents hydrogen;

R 1f represents hydrogen;

R 1g represents hydrogen or fluoro;

R 2 represents C 1 -C 2 -haloalkyl;

R 3 represents phenyl, wherein said phenyl is independently optionally substituted, one or more times, with halogen or methyl;

R 4a represents hydrogen, halogen, or methyl;

R 4b represents hydrogen, halogen, C 1 -C 4 -alkyl, C 1 -C 3 -haloalkyl-CH 2 —, C 1 -C 3 -alkoxy, C 1 -C 3 -haloalkoxy, C 3 -cycloalkyl, C 3 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -cycloalkyl-O—, C 3 -cycloalkyl-CH 2 —O—, piperazin-1-yl, morpholin-4-yl, 3- to 6-membered heterocycloalkyl connected via a carbon atom thereof, pyrrolidin-2-one, piperidin-2-one, morpholin-3-one, 4-methylpiperazin-2-one, 3- to 6-membered heterocycloalkyl-O— or 3- to 6-membered heterocycloalkyl-CH 2 —O—, C 1 -C 3 -alkoxy-C 2 -C 3 -alkoxy-, C 1 -C 4 -hydroxyalkyl, or C 1 -C 4 -hydroxyalkyl-O—,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

4 . A compound of formula (I) according to claim 1 , which is a compound of formula (XXIII)

wherein:

X represents C—H, or C—F;

Y represents N or C—R 4a ;

Z represents N or C—R 4b ;

wherein none or one of Y and Z represent N;

R 1b represents hydrogen or fluoro;

R 1e represents hydrogen;

R 1f represents hydrogen;

R 1g represents hydrogen or fluoro;

R 4a represents hydrogen, halogen, or methyl;

R 4b represents hydrogen, halogen, C 1 -C 4 -alkyl, C 1 -C 3 -haloalkyl-CH 2 —, C 1 -C 3 -alkoxy, C 1 -C 3 -haloalkoxy, C 3 -cycloalkyl, C 3 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -cycloalkyl-O—, C 3 -cycloalkyl-CH 2 —O—, piperazin-1-yl, morpholin-4-yl, 3- to 6-membered heterocycloalkyl connected via a carbon atom thereof, pyrrolidin-2-one, piperidin-2-one, morpholin-3-one, 4-methylpiperazin-2-one, 3- to 6-membered heterocycloalkyl-O— or 3- to 6-membered heterocycloalkyl-CH 2 —O—, C 1 -C 3 -alkoxy-C 2 -C 3 -alkoxy-, C 1 -C 4 -hydroxyalkyl, or C 1 -C 4 -hydroxyalkyl-O—,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

5 . The compound of formula (I) according to claim 1 , which is selected from the group consisting of:

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[5-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[5-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[5-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-[4-(6-fluoro-3-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-[4-(6-fluoro-3-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-[4-(6-fluoro-3-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-[4-(3-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-[4-(3-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-[4-(3-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl]butanamide; and

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-(6-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-(6-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-(6-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

N-{4-[7-(2,2-difluoroethoxy)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[7-(2,2-difluoroethoxy)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[7-(2,2-difluoroethoxy)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

4,4-difluoro-N-{4-[5-fluoro-6-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-6-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-6-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-7-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-7-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-methoxy-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-7-methoxy-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-7-methoxy-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

N-{4-[7-(cyclopropyloxy)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[7-(cyclopropyloxy)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[7-(cyclopropyloxy)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

N-{4-[7-(cyclopropylmethyl)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[7-(cyclopropylmethyl)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[7-(cyclopropylmethyl)-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

N-{4-[7-chloro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

N-{4-[7-{[(2R)-1,4-dioxan-2-yl]methoxy}-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[7-{[(2R)-1,4-dioxan-2-yl]methoxy}-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[7-{[(2R)-1,4-dioxan-2-yl]methoxy}-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-{[(3S)-oxolan-3-yl]oxy}-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-7-{[(3S)-oxolan-3-yl]oxy}-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-7-{[(3S)-oxolan-3-yl]oxy}-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-(4-methylpiperazin-1-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

N-(4-{7-[(2S)-1,4-dioxan-2-ylmethoxy]-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[7-{[(2S)-1,4-dioxan-2-yl]methoxy}-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[7-{[(2S)-1,4-dioxan-2-yl]methoxy}-5-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-fluoro-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-{[oxolan-2-yl]methoxy}-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[2-fluoro-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[2-fluoro-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[2-fluoro-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[3,2-c]pyridazin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[3,2-c]pyridazin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[3,2-c]pyridazin-6-yl]pyridin-2-yl}butanamide;

N-{4-[3-chloro-7-(pyridin-2-yl)-5H-pyrrolo[3,2-c]pyridazin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-(morpholin-4-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

N-{4-[5-chloro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

N-(4-(6-fluoro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-2-(4-fluorophenyl)-3-hydroxypropanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[4-{[(3S)-oxolan-3-yl]oxy}-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[4-{[(3S)-oxolan-3-yl]oxy}-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[4-{[(3S)-oxolan-3-yl]oxy}-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

N-{4-[7-(2,2-difluoroethoxy)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[7-(2,2-difluoroethoxy)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[7-(2,2-difluoroethoxy)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

N-{4-[4-(2,2-difluoroethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[4-(2,2-difluoroethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[4-(2,2-difluoroethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-methoxy-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-methoxy-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[6-methoxy-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-methyl-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-methyl-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-methyl-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-methyl-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

N-{4-[6-chloro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[6-chloro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[6-chloro-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-(2-methoxyethoxy)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-7-(2-methoxyethoxy)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-7-(2-methoxyethoxy)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(piperazin-1-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(piperazin-1-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(piperazin-1-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}butanamide;

4,4-difluoro-N-{4-[5-fluoro-3-(4-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-3-(4-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-3-(4-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-7-(2-hydroxypropan-2-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-7-(2-hydroxypropan-2-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-7-(2-hydroxypropan-2-yl)-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-methoxy-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-methoxy-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[3-methoxy-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

2-(4-fluorophenyl)-4-hydroxy-N-(4-(3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)-butanamide;

N-{4-[3-(difluoromethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[3-(difluoromethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[3-(difluoromethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

4,4-difluoro-N-{4-[5-fluoro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-{4-[5-fluoro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-{4-[5-fluoro-3-(5-fluoropyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}-2-(4-fluorophenyl)butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-[4-(3-pyrimidin-2-yl-1H-pyrrolo[3,2-b]pyridin-2-yl)-2-pyridyl]butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[4-methoxy-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-(4-{5-fluoro-3-(pyridin-2-yl)-7-[tetrahydrofuran-2-yl]-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl) butanamide;

(2R)-4,4-difluoro-N-(4-{5-fluoro-7-[(2R)-oxolan-2-yl]-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)-2-(4-fluorophenyl)butanamide;

(2R)-4,4-difluoro-N-(4-{5-fluoro-7-[(2S)-oxolan-2-yl]-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-(4-{5-fluoro-7-[(2R)-oxolan-2-yl]-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)-2-(4-fluorophenyl)butanamide;

(2S)-4,4-difluoro-N-(4-{5-fluoro-7-[(2S)-oxolan-2-yl]-3-(pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl}pyridin-2-yl)-2-(4-fluorophenyl)butanamide;

4,4,4-trifluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4,4-trifluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4,4-trifluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-6-yl]pyridin-2-yl}butanamide;

4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-4-(2,2,2-trifluoroethoxy)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-4-(2,2,2-trifluoroethoxy)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-4-(2,2,2-trifluoroethoxy)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

4,4,4-trifluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-4-(2,2,2-trifluoroethoxy)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2R)-4,4,4-trifluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-4-(2,2,2-trifluoroethoxy)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

(2S)-4,4,4-trifluoro-2-(4-fluorophenyl)-N-{4-[7-(pyridin-2-yl)-4-(2,2,2-trifluoroethoxy)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}butanamide;

N-{4-[4-(cyclopropylmethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2R)—N-{4-[4-(cyclopropylmethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

(2S)—N-{4-[4-(cyclopropylmethoxy)-7-(pyridin-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl]pyridin-2-yl}-4,4-difluoro-2-(4-fluorophenyl)butanamide;

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

6 . A method of preparing a compound of general formula (I) according to claim 1 , said method comprising reacting an intermediate compound of general formula (VII-A):

wherein A, X, Y and Z are as defined for the compound of general formula (I) according to claim 1 ,

with an acylating reagent selected from:

a) a carboxylic acid of formula

b) an acyl halide of formula

wherein Ha1 represents F, C 1 or Br, or

c) an anhydride of formula

wherein R 2 and R 3 are as defined for the compound of general formula (I) according to claim 1 ,

to give a compound of general formula (I):

wherein R 2 , R 3 , A, X, Y and Z are as defined for the compound of general formula (I) according to claim 1 .

7 . A method of treating or preventing a hyperproliferative disease and/or a disorder responsive to induction of cell death in a subject, comprising administering a compound of general formula (I) according to claim 1 to the subject.

8 . The method according to claim 7 , wherein the hyperproliferative disease and/or disorder responsive to induction of cell death are a haematological tumour, solid tumour and/or metastases thereof.

9 . The method according to claim 8 , wherein the haematological tumour is a lymphoma and/or metastases thereof.

10 . The method according to claim 9 , wherein the lymphoma is diffuse large B-cell lymphoma and/or metastases thereof.

11 . The method according to claim 8 , wherein the solid tumour is a cervical tumour, a lung tumour, a colon tumour and/or metastases thereof.

12 . The method according to claim 11 , wherein the lung tumour is a lung carcinoma and/or metastases thereof.

13 . The method according to claim 11 , wherein the colon tumour is a colorectal carcinoma and/or metastases thereof.

14 . A pharmaceutical composition comprising at least one compound of general formula (I) according to claim 1 , together with at least one pharmaceutically acceptable excipient.

15 . A method of treating haematological tumours, solid tumours and/or metastases thereof in a subject, comprising administering a composition according to claim 14 to the subject.

16 . A combination comprising one or more first active ingredients selected from a compound of general formula (I) according to claim 1 , and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.

17 . An intermediate compound of general formula (IX-Q), (IX-A), (XIV-Q), or (XVII), or a salt thereof:

wherein R 2 , R 3 , A, X, Y and Z are as defined for the compound of general formula (I) according to claim 1 , T represents CF 3 —C(O)—, mesylate, tosylate or Ph-SO 2 —, wherein Ph can be substituted one, two or three times with halogen or a methyl-group or a nitro-group, Q represents a chloro, a bromo or an iodo, and PG represents a protecting group.

18 . A method of preparing a compound of general formula (I) according to claim 1 , said method comprising reacting an intermediate compound of general formula (XIV-Q):

wherein R 2 , R 3 , X, Y and Z are as defined for the compound of general formula (I) according to claim 1 , and Q represents a chloro, a bromo or an iodo,

with a stannane, such as, for example, A-Sn (Bu) 3, a boronic acid A-B (OH) 2 or a boronic acid ester thereof, wherein A is as defined for the compound of general formula (I), in the presence of a palladium catalyst,

to prepare compounds of general formula (I).

19 . A method of preparing a compound of general formula (I) according to claim 1 , said method comprising reacting an intermediate compound of general formula (XVII):

wherein R 2 , R 3 , X, Y and Z are as defined for the compound of general formula (I) according to claim 1 , and T represents CF 3 —C(O)—, mesylate, tosylate or Ph-SO 2 —, wherein Ph can be substituted one, two or three times with halogen, methyl or a nitro, with a suitable bromide A-Br or iodide A-I wherein A is as defined for the compound of general formula (I) in the presence of a palladium catalyst, in a Cacchi reaction, to prepare compounds of general formula (I) or, optionally, to prepare compounds of general formula (I) after removal of the group T.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: BAYER HEALTHCARE LLC
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 068023/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: BREZEZINKA, KRZYSZTOF
To: NUVISAN ICB GMBH
Reel/Frame 068022/0987 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: NUVISAN ICB GMBH
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 068022/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: RUPAIMOOLE, RAJESHA
To: BAYER HEALTHCARE LLC
Reel/Frame 068022/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: SCHULZE, VOLKER; MENGEL, ANNE; FARIA ALVARES DE LEMOS, CLARA ADELAIDE; CHRISTIAN, SVEN; BÖMER, ULF; HILLIG, ROMAN; LECHNER, CHRISTIAN; MORTIER, JÉRÉMIE XAVIER; KAULFUSS, STEFAN; BERGER, MARKUS; LIENAU, PHILIP
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 068022/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2023
From: HANDING, KATARZYNA; MADEC, AMAEL; FURST, LAURA; SHEKHAR, MRINAL; ORSI, DOUGLAS; MCKINNEY, DAVID
To: THE BROAD INSTITUTE, INC.
Reel/Frame 065041/0054 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 062928 FRAME: 0045. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Apr 5, 2023
From: CORSELLO, STEVEN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 063255/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2023
From: CORSELLO, STEVEN
To: DANA-FARBER CANCER INSITITUTE, INC.
Reel/Frame 062928/0045 →
Continuity (3)
Provisional Application 63181064 · Apr 28, 2021
Provisional Application 63058237 · Jul 29, 2020
Related Publication 20230391769A1 · Dec 7, 2023
References Cited (50)
US 8084395B2 · Selles · 2011 [cited by examiner]
US 8546413B2 · Marchionni et al. · 2013 [cited by applicant]
US 12227501B2 · Schulze et al. · 2025 [cited by applicant]
US 20040209897A1 · Vernier et al. · 2004 [cited by applicant]
US 20160176871A1 · Fink et al. · 2016 [cited by applicant]
US 20230046077A1 · Schulze et al. · 2023 [cited by applicant]
US 20230322767A1 · Schulze et al. · 2023 [cited by applicant]
US 20230339939A1 · Schulze et al. · 2023 [cited by applicant]
US 20230365554A1 · Schulze et al. · 2023 [cited by applicant]
US 20250188075A1 · Orsi et al. · 2025 [cited by applicant]
WO WO9920624A1 · 1999 [cited by applicant]
WO WO2005013986A1 · 2005 [cited by applicant]
WO WO2007067506A2 · 2007 [cited by applicant]
WO WO2008132434A2 · 2008 [cited by examiner]
WO WO2010046215A2 · 2010 [cited by applicant]
WO WO2010070237A1 · 2010 [cited by applicant]
WO WO2010070238A1 · 2010 [cited by applicant]
WO WO2011053476A1 · 2011 [cited by applicant]
WO WO2015073763A1 · 2015 [cited by applicant]
WO WO2015195880A1 · 2015 [cited by applicant]
WO WO2016100166A1 · 2016 [cited by applicant]
WO WO2016120196A1 · 2016 [cited by applicant]
WO WO2017079558A1 · 2017 [cited by applicant]
WO WO2020161257A1 · 2020 [cited by applicant]
WO WO2022023337A1 · 2022 [cited by applicant]
WO WO2022023339A1 · 2022 [cited by applicant]
WO WO2022023340A1 · 2022 [cited by applicant]
WO WO2022023341A1 · 2022 [cited by applicant]
WO WO2023147015A1 · 2023 [cited by applicant]
Chen H. et al. Azoxystrobin Reduces Oral Carcinogenesis by Suppressing Mitochondrial Complex III Activity and Inducing Apoptosis. Cancer Management and Research (12) 11573-11583 (2020). (Year: 2020). [cited by examiner]
Meanwell, N.A. Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. J. Med. Chem. 61, 5822-5880 (2018). (Year: 2018). [cited by examiner]
Golub et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.” Science 286 (1999): 531-537. [cited by applicant]
Lala et al., “Role of nitric oxide in tumor progression: lessons from experimental tumors.” Cancer and Metastasis Reviews 17 (1998): 91-106. [cited by applicant]
MedlinePlus, “Cancer” (2007): 10 pages. [cited by applicant]
U.S. Appl. No. 17/428,730, Published. [cited by applicant]
U.S. Appl. No. 18/018,207, Published. [cited by applicant]
U.S. Appl. No. 18/018,221, Published. [cited by applicant]
U.S. Appl. No. 18/018,148, Published. [cited by applicant]
U.S. Appl. No. 18/833,767, Pending. [cited by applicant]
Bibian, Mathieu, et al. Development of highly selective casein kinase 1delta/1 epsilon (CK1delta/epsilon) inhibitors with potent antiproliferative properties. Bioorganic & medicinal chemistry letters, 2013, 23.15: 4374-… [cited by applicant]
Huart, Anne-Sophie, et al. A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway. Bioorganic & medicinal chemistry letters, 2013, 23.20: 5578-5585. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/011694 dated Apr. 27, 2023. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/070992 dated Nov. 3, 2021. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/070994 dated Oct. 27, 2021. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/070996 dated Nov. 19, 2021. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/070998 dated Oct. 20, 2021. [cited by applicant]
Jaras, Marcus, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. Journal of Experimental Medicine, 2014, 211.4: 605-612. DOI: <10.1084/jem.20131033>. Published: Mar. 10, 2014. [cited by applicant]
Knippschild, Uwe, et al. The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Frontiers in oncology, 2014, 4: 96. Published: May 19, 2014. [cited by applicant]
Shanware, Naval P., et al. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB reports, 2009, 42.3: 142. doi: 10.5483/bmbrep.2009.42.3.142. Published: Mar. 31, 2… [cited by applicant]
International Search Report for International Application No. PCT/EP2020/053020 dated May 6, 2020. [cited by applicant]